The role of surgery in primary hyperthyroidism A P Weetman DSc FRCP SECTIONS OF ENDOCRINOLOGY, PATHOLOGY AND SURGERY The vast majority of patients with primary hyperthyroidism have Graves' disease, toxic multinodular goitre or solitary toxic adenoma. The role of surgery in each of these varies and is, perhaps, most contentious in Graves' disease, the commonest cause of hyperthyroidism. The alternatives are antithyroid drugs and radioiodine. The place of surgery will be discussed after considering the advantages and disadvantages of these treatments. However, as none of these treatments is ideal, novel therapeutic approaches seem warranted, particularly in Graves' disease. ANTITHYROID 
DRUGS
In the UK, carbimazole is the most widely used antithyroid drug: propylthiouracil and methimazole are popular elsewhere. All are thionamides and reduce the production of thyroid hormones by inhibiting the key enzyme thyroid peroxidase, leading to impaired organification of iodine and reduced iodotyrosine coupling. Propylthiouracil inhibits the conversion of thyroxine (T4) to triiodothyronine (T3), leading to a slightly faster amelioration of hyperthyroidism, but this is only of importance in thyroid storm. In addition, antithyroid drugs have direct effects on the autoimmune process, leading to a fall in the thyroid stimulating antibodies which cause Graves' disease1. The apparent specificity of this action probably resides in the concentration of drug within the thyroid cells, reducing the release of proinflammatory molecules2. In turn, this will reduce the thyroid lymphocytic infiltrate and lower thyroid antibody production.
In some patients the immunological effects of antithyroid drugs are sufficient to induce a sustained, even permanent, remission which is the justification for their use as first line treatment in many patients with Graves' disease. However, these drugs have no effect on the underlying causes of toxic multinodular goitre or toxic adenoma, with recurrence occurring soon after the biochemical effects wear off. The use of antithyroid drugs in these conditions is restricted to control of hyperthyroidism prior to definitive treatment with radioiodine or surgery; some also favour long-term low-dose antithyroid drugs in the elderly particularly with limited life expectancy3.
University of Sheffield, Sheffield, UK Unfortunately, there are no reliable predictors of outcome after antithyroid drugs in Graves' disease, despite many attempts which have focused on immunogenetic markers and thyroid stimulating antibody levelsF6. However, patients with a large goitre have a low chance of remission, and those who have relapsed after one course of drugs are also unlikely to achieve a sustained remission. Attempts to improve outcome have recently centred on using combinations of antithyroid drugs and T4, the socalled block-replace regimen. Although superior to the traditional titration regimen in one study7, this has not been the experience in Europe8 where results may have been influenced by a relatively low iodine intake. However, there is little dispute that remission rates are increased after prolonged use (around 2 years) of the titration regimen9'10, whereas the same rates are achieved with 6 months of the block-replace method6. Clinic visits are fewer and therefore costs are lower with this latter regimen.
A novel strategy has been to continue T4 at the end of a course of the block-replace regimen, which has produced a remarkably low relapse rate in Japan11. Confirmation of these results in other countries is awaited. Unfortunately, this has not been confirmed in the UK12.
The advantages and disadvantages of antithyroid drugs for the treatment of Graves' disease are summarized below: Advantages * Rapid control of symptoms * Short course of block-replace regimen simple to administer * Can be used in pregnancy and while breast feeding * Treatment of choice in children and adolescents * No deterioration of ophthalmopathy. Disadvantages * Side-effects, especially rash, fever and arthralgia; granulocytopenia is the most serious * Remission in around 40% of patients * Outcome cannot be predicted (but relapse very likely with a large goitre or after a previous unsuccessful course) * Hypothyroidism (late onset in 15% of patients in remission).
Their biggest drawback is the unpredictable and poor remission rate. In a series of 434 Scottish patients, the culmulative relapse rate was 55% at 5 years and 61% at 10 years13. Thereafter, relapse seemed to occur very rarely, but a continuing, albeit small, risk has been observed in Ireland10. On the other hand, antithyroid drugs rapidly improve the clinical status of patients, and the trial of a short (6-month) course seems warranted in most young patients. Antithyroid drugs given as a titration regimen are the treatment of choice for Graves' disease in pregnancy and also as an extended course for children and adolescents, until a convenient time for surgery to be considered in relation to schooling.
RADIOIODINE
Hyperthyroidism is the only major non-malignant disease in which radiation is used extensively in treatment14. Despite its use since 1941, radioiodine treatment has not been standardized and many different doses are recommended15.
Recommendations for treatment have been produced recently by the Royal College of Physicians of London
Radioiodine Audit Subcommittee16. The aim of treatment is to destroy sufficient thyroid tissue to render the patient euthyroid as quickly as possible but innate biological variability in target organ susceptibility makes accurate dosimetry impossible, leading to a certain percentage of patients requiring retreatment whichever policy is adopted. Deliberate attempts to ablate the thyroid using relatively high doses of radioiodine do not achieve their aim in up to a third of patients 1 year after treatment17. Furthermore, radiation-induced latent damage to the nuclei of thyroid follicular cells, combined with autoimmune effects, lead to at least 10%-1 5% of patients becoming hypothyroid in the first year17 and a continued 2%-3% annual rate of hypothyroidism in the years after radioiodine, when nonablative doses are given. Attempts to reduce these rates by using lower doses of radioiodine simply result in more patients requiring a second dose.
Although these results from radioiodine are clearly imperfect, the cure of hyperthyroidism at the expense of hypothyroidism seems a price worth paying, particularly as no current treatment is free of this consequence. The other advantages and disadvantages of radioiodine are: Advantages * Simple; can be repeated * Cheap. Disadvantages * Contraindicated in pregnancy and breast feeding * Need to avoid close contact with children for 2-3 weeks after treatment * Cancer risk: overall nil but see text * Genetic risk: insignificant but see text * Ophthalmopathy may worsen after radioiodine * Hypothyroidism: requires life-long follow-up (not specific to radioiodine) * Limited effect on goitre size.
Three deserve further comment.
First, the genetic risks of radioiodine are remote, increasing the risk of a child having a harmful trait by 0.002% or less, compared to a spontaneous risk of such abnormalities of 0.8%18. It is unlikely that any excess risks of congenital malformations are serious but such treatment is contraindicated in pregnancy: conception should be avoided for at least 4 months after radioiodine.
Secondly, there is no overall increase in cancer risk after radioiodine19. The apparent increase in leukaemia originally observed seems to be an association of this malignancy with hyperthyroidism itself14. However, the recent report of a significant increase in gastric cancer appearing more than 10 years after radioiodine, particularly in younger patients19,20
continues to raise questions about carcinogenesis. Such results have prompted calls for caution in lowering age limits for radioiodine treatment19, although this varies greatly throughout the world. No doubt continued followup will ultimately provide conclusive results. At present, there seem sufficient grounds to reassure patients but radioiodine should be given to children as a last resort. The final area of concern has been the suggestion that radioiodine may exacerbate thyroid-associated ophthalmo-pathy21'22 but neither trial provides conclusive supporting evidence. In the first trial patients who received radioiodine without prophylactic steroids fared worse than those who also received steroids2l, but the deterioration in eye signs was slight and there were no controls (i.e. not treated with radioiodine) to prove that any deterioration was indeed due to radioiodine. In the second22, three groups of Graves' patients were treated with antithyroid drugs, surgery or radioiodine: eye signs were significantly more frequent after radioiodine treatment. However, the main drawbacks to this study are: (i) the groups were not matched, with more smokers in the radioiodine-treated group (smoking is a major risk factor for ophthalmopathy); and (ii) many in the radioiodine-treated group developed hypothyroidism which may exacerbate ophthalmopathy. An extensive review of the effects of treatment on ophthalmopathy indicates that radioiodine-induced exacerbation must be infrequent23.
However, until further definitive trials are conducted, it 8 Supplement No. 33 Volume 91 1 9 9 8 seems at least prudent to warn a Graves' patient who already has severe eye signs of this potential effect of radioiodine and offer frequent follow-up with or without prophylactic steroids.
Radioiodine is particularly effective treatment for hyperthyroidism due to toxic nodular disease of thyroid as the suppressed extranodular tissue does not concentrate radioiodine. This normal tissue is, therefore, usually protected from destruction, leading to a lower incidence of hypothyroidism than in Graves' disease and an excellent cure rate even when modest doses of radioiodine are used17,24. However, very large multinodular goitres may require massive doses necessitating hospital admission17, shrinkage of such goitres is usually only slight or moderate. SURGERY For Graves' disease and toxic multinodular goitre, the aim of surgery is to remove sufficient thyroid tissue to render the patient euthyroid with minimal rates of recurrence or hypothyroidism. A subtotal thyroidectomy is usually performed, although some centres perform near-total thyroidectomy. In Graves' disease, surgery may also directly affect the autoimmune process, for instance by removing autoantigen and thyroid infiltrating lymphocytes, but the evidence for this is controversial25'26. Surgery for a toxic adenoma aims to remove the solitary causal lesion, usually by lobectomy, with fewer resulting complications, including hypothyroidism.
The disadvantages and complications of surgery have been reviewed recently27'28. No single factor, other than remnant size, predicts thyroid function after surgery for Graves' disease29. The risk of recurrence should be less than 5% although such rates are associated with an increased risk of hypothyroid-ism27. When recurrence after surgery is treated with radioiodine, the risks of hypothyroidism are very high30. There is a continued risk of recurrence for at least 10 years after inadequate surgery31.
Even more than with radioiodine, it is preferable to accept the occurrence of hypothyroidism as the cost of successful treatment, a risk which in any case is shared by all three forms of therapy. The rates of hypothyroidism vary widely between series, in part related to the duration of follow-up. In one large series from Ireland 10% of patients were hypothyroid after 5 years and 18% after 10 years10, the risk of hypothyroidism continues, and even increases, after this time32. The factors which influence recurrence or remnant failure are: * Age: recurrence more common over 30 * Goitre size: hypothyroidism more likely with small goitre * Remnant size: relationship to recurrence not direct * Iodine intake: recurrence higher with increased intake * Immunologicalfactors: persistence of thyroid stimulating antibodies associated with recurrence * High levels of thyroid peroxidase antibodies and extensive lymphocytic infiltrate associated with increased risk of hypothyroidism.
The immunological sequelae of partial thyroidectomy may be of critical importance; while these remain poorly understood, improved results from surgery seem unlikely.
Toxic multinodular goitre usually occurs in patients over 50 and radioiodine is the treatment of choice. However, surgery may be preferable in patients with a very large goitre who are bothered by pressure effects or cosmetic appearance, as goitre shrinkage after radioiodine may only be modest. Patients with a retrosternal extension of their goitre are a particular group in whom surgery is indicated to prevent or relieve airway obstruction33. Toxic adenoma can also be treated with radioiodine, as described above, but thyroid lobectomy is also very effective34. This latter approach seems indicated in younger patients, particularly if there is any uncertainty about the nature of the thyroid pathology.
There are few absolute indications for thyroid surgery in the treatment of primary hyperthyroidism. Moreover, there are marked variations internationally in the use of surgery35'36. Careful and detailed explanation to the patient of the three major types of treatment with their advantages and disadvantages is essential and, ultimately, patient preference is the reason for the choice of any form of 9 thyroid treatment. Although this perhaps states the obvious, patients who have hyperthyroidism require life-long followup. The control of their disease can sometimes be a long and frustrating process, associated with concerns about associated eye disease. Patients must have a clear idea of what to expect from any form of treatment, including surgery, to help them cope with what can be a prolonged serious illness.
My own policy is to recommend surgery in the following situations: * Graves' disease at initial presentation in a patient under 40 with ophthalmopathy and a very large goitre, once hyperthyroidism is controlled with antithyroid drugs * Any accompanying nodular disease with uncertain pathology (e.g. nodule in Graves' disease, a dominant nodule in a multinodular goitre) after fine needle aspiration biopsy * To cure Graves' disease prior to a planned pregnancy or for pregnant patients who cannot tolerate or who fail to respond to antithyroid drugs. Although radioiodine is an alternative before pregnancy, surgery is the only option during pregnancy * Patient preference either after relapse of Graves' disease following antithyroid drugs or as primary treatment for toxic multinodular goitre or toxic adenoma.
In particular, until further information becomes available, I would favour surgery over radioiodine for children and adolescents who cannot or do not wish to take antithyroid drugs. Surgery is also indicated if there is any risk of airways obstruction from a large goitre, particularly if retrosternal.
